Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835051 | 0.91 | L3MBTL1 (0.46) | L3MBTL1LMNAMAPTTDP1MAPK1 | |
| SCHEMBL26290435 | 0.83 | MAPT (0.50) | L3MBTL1LMNAMAPTTDP1MAPK1 | |
| SCHEMBL21137880 | 0.81 | HK1 (0.39) | L3MBTL1LMNAMAPTMAPK1ALDH1A1 | |
| SCHEMBL25839726 | 0.81 | L3MBTL1 (0.45) | L3MBTL1LMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL25835954 | 0.81 | L3MBTL1 (0.45) | L3MBTL1LMNAMAPTTDP1MAPK1 | |
| SCHEMBL21138213 | 0.79 | LMNA (0.37) | L3MBTL1LMNATDP1ALDH1A1KMT2A | |
| SCHEMBL21137906 | 0.77 | PYGB (0.44) | L3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL18365284 | 0.76 | HK1 (0.49) | — | |
| SCHEMBL5981575 | 0.76 | MAPT (0.51) | L3MBTL1LMNAMAPTTDP1MAPK1 | |
| SCHEMBL30681167 | 0.76 | MAPT (0.51) | L3MBTL1LMNAMAPTTDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | L3MBTL1 3561/4885LMNA 2632/4885MAPT 3677/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | L3MBTL1 3561/4885LMNA 2632/4885MAPT 3677/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | L3MBTL1 4558/4885LMNA 2743/4885MAPT 2761/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | L3MBTL1 4558/4885LMNA 2743/4885MAPT 2761/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | L3MBTL1 4558/4885LMNA 2743/4885MAPT 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.